CoreAge Rx vs Pallas Health

Strengths

• +Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
• +Advertises the same price across doses and no membership fee
• +Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

• –Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
• –FAQ no-rebill and payment-timing statements differ from the subscription and order policy
• –FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
• –Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
• –Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation

Strengths

• +Names six dispensing pharmacies outright on a public page — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — and explains the 503A versus 503B distinction alongside them. Almost nothing else in this ranking names one at all
• +Two prescribing physicians are named with their NPI numbers and a "verify in the NPPES registry" link: Dr. Ana Lisa Carr, MD (NPI 1689841744, licensed in 15 states) and Dr. Kelly Tenbrink, MD (NPI 1346482684, licensed in Tennessee and Florida). Both resolve to active NPPES records
• +LegitScript Healthcare Merchant certified (seal 49989444), and the FDA's warning-letter index carries nothing against Pallas Health, its operator Brentmoor, Inc., or the CareValidate platform it runs on
• +The marketing price is the checkout price — the homepage FAQ, the landing pages, the treatment pages and the live funnel all state the same figures, and no step-up appears at the payment screen
• +Canceling is self-serve and free with no minimum term: a portal at pallashealth.co/portal, an email reminder before each renewal, at least 30 days' notice before any price change, and a full refund if a clinician declines you
• +All 50 states and Washington, D.C., asynchronous in 43 of them, FSA/HSA eligible per the site banner, free shipping when prescribed — plus a brand-name lane (Zepbound, Ozempic, Wegovy, Mounjaro) that is genuinely billed monthly

What to consider

• –There is no month-to-month rung for either compounded molecule — the funnel renders no cadence selector at all. After $139 for the first four weeks the second charge is $597, in one go, four weeks later; on tirzepatide it is $179 and then $897
• –Twelve weeks is not three months. The renewal recurs every 84 days — 4.348 times a year, not 4 — while the advertised average divides one twelve-week prepay by 3. On Pallas's own published renewal terms the steady state is $2,596/yr (about $216/mo) on semaglutide and $3,900/yr (about $325/mo) on tirzepatide: roughly 8.7% above the advertised averages
• –$139 and $179 are first-period rates only, and the sitewide "Up to $120 off your first month" banner is a discount, not a price
• –Whether baseline or follow-up lab work is included or costs extra is not published anywhere, and there is no pre-purchase dose selector — so whether the price rises with dose, beyond the flat claim, is not published either
• –Only two clinicians are named site-wide, and the footer's "Provider directory" link resolves to the section naming those same two. The actual prescribing network — Lion MD's affiliated professional corporations — is not published. NPPES confirms Dr. Carr's family-medicine taxonomy; the obesity and addiction medicine board certifications the site claims for her are not verifiable through NPPES and we did not check them independently
• –One of the six named dispensing pharmacies, Belmar, received an FDA warning letter issued March 2023 over compounding practices, addressed to "Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy" — which the FDA CLOSED OUT in October 2023. It is a disclosure about a supplier; Pallas Health carries no warning letter of its own
• –The compounded semaglutide and tirzepatide are not FDA-approved and are not generic equivalents of Wegovy or Zepbound. Pallas discloses this properly, but it still bounds what the medication is
• –No insurance, ever. The brand-name lane runs $1,069/mo for Zepbound up to $1,349/mo for Wegovy and Mounjaro, cash — far above what an insured patient pays for the same product
• –$5 is deducted from each refunded payment on purchases made on or after 14 July 2026 (never on a clinician-declined or unfulfilled order, which refund in full). In the seven states that require a video visit — Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia — plus Washington, D.C., a $60 visit deposit can be retained if you neither attend nor reschedule and then abandon the intake
• –The site's own footer states that "Some content on this site is AI-generated; no representation or warranty is made regarding its accuracy, completeness, or reliability" — so its blog is not a source for a clinical claim. The advertised "4.8" rating has no published source, and the before/after "Verified Customer" stories carry a note that the individuals shown may be actors or models
• –New here — first tracked in July 2026 — with no Trustpilot or BBB record published to cross-check it against